<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511415890</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511415890</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letter to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Comment on the article by Stauch et al. ‘Intrathecal IgM synthesis in paediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis’</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Villar</surname><given-names>LM</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511415890">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Álvarez-Cermeño</surname><given-names>JC</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511415890">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511415890"><label>1</label>Immunology Department, MS Unit, Hospital Ramon y Cajal, Madrid, Spain</aff>
<aff id="aff2-1352458511415890"><label>2</label>Neurology Department, MS Unit, Hospital Ramon y Cajal, Madrid, Spain</aff>
<author-notes>
<corresp id="corresp1-1352458511415890">Dr Luisa M Villar, Immunology Department, MS Unit, Hospital Ramon y Cajal, Cra. Colmenar km 9.100, Madrid, Spain Email: <email>lvillar.hrc@salud.madrid.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>2</issue>
<fpage>250</fpage>
<lpage>251</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>The article by Stauch et al.<sup><xref ref-type="bibr" rid="bibr1-1352458511415890">1</xref></sup> addresses two main points: First, they report the inability of intrathecal IgM synthesis calculated with Reiber’s semi-quantitative formula (Reibergram) in predicting the progression of paediatric multiple sclerosis (MS). Second, they compared their results with those obtained by us measuring intrathecal IgM synthesis by oligoclonal IgM band detection in adult onset MS.<sup><xref ref-type="bibr" rid="bibr2-1352458511415890">2</xref></sup> Using our previously published data, they calculated the IgM Reibergram in our patients. Since many of our positive results were negative with that formula, they considered our results as false positives.</p>
<p>This is surprising, because it has been recognized that oligoclonal detection is the gold standard in demonstrating intrathecal immunoglobulin synthesis, since it shows higher sensitivity that semi-quantitative formulae.<sup><xref ref-type="bibr" rid="bibr3-1352458511415890">3</xref>,<xref ref-type="bibr" rid="bibr4-1352458511415890">4</xref></sup> In line with this, this group described that a negative value of Reiber formula occurred in 20–30% of both adult and paediatric onset multiple sclerosis patients showing oligoclonal IgG bands.<sup><xref ref-type="bibr" rid="bibr5-1352458511415890">5</xref>,<xref ref-type="bibr" rid="bibr6-1352458511415890">6</xref></sup> In that case, they considered that oligoclonal band detection was more accurate than Reibergram and did not consider their IgG bands as false positives.</p>
<p>Oligoclonal band study has also been reported as the best method to investigate intrathecal IgM synthesis.<sup><xref ref-type="bibr" rid="bibr7-1352458511415890">7</xref></sup> Analysis of oligoclonal IgM bands is more difficult than that of IgG, since IgM is a pentamer that shows high molecular weight and is difficult to separate by isoelectrofocusing (IEF) it its native form. To overcome this, two methods were developed that included reduction of inter-chain disulphide bonds of IgM pentamers to convert them to monomers before IEF.<sup><xref ref-type="bibr" rid="bibr8-1352458511415890">8</xref>,<xref ref-type="bibr" rid="bibr9-1352458511415890">9</xref></sup> The problem was that when disulphide bond reductions are performed at neutral pH, as described in those methods, they are often incomplete.<sup><xref ref-type="bibr" rid="bibr10-1352458511415890">10</xref></sup> This may render artefacts that can be confounded with oligoclonal bands as described by Schneider et al.<sup><xref ref-type="bibr" rid="bibr11-1352458511415890">11</xref></sup> who when using one of these methods found that nearly all patients showed faint IgM bands. To prevent these confounding results, we described a method to study oligoclonal IgM bands including a reduction of IgM at alkaline pH, which produces a complete reduction of IgM, avoiding false-positive results.<sup><xref ref-type="bibr" rid="bibr12-1352458511415890">12</xref></sup> Examples of our positive and negative IgM blots are shown in <xref ref-type="fig" rid="fig1-1352458511415890">Figure 1</xref>.</p>
<fig id="fig1-1352458511415890" position="float">
<label>Figure 1.</label>
<caption>
<p>Oligoclonal IgM analysis of five serum (S) / cerebrospinal fluid (CSF, C) pairs from five multiple sclerosis patients. Patients 2, 4 and 5 showed oligoclonal IgM bands restricted to CSF. Patients 1 and 3 showed a polyclonal patterns in serum and CSF.</p>
</caption>
<graphic xlink:href="10.1177_1352458511415890-fig1.tif"/>
</fig>
<p>Using this method, we explored intrathecal IgM synthesis in neurological patients. We only found positive patterns in infectious diseases of the central nervous system (CNS) and in MS.<sup><xref ref-type="bibr" rid="bibr13-1352458511415890">13</xref></sup> The presence of oligoclonal IgM bands is associated with a poor outcome in MS.<sup><xref ref-type="bibr" rid="bibr2-1352458511415890">2</xref>,<xref ref-type="bibr" rid="bibr14-1352458511415890">14</xref></sup> Our results were validated in blind studies performed by our group in other cohorts<sup><xref ref-type="bibr" rid="bibr15-1352458511415890">15</xref>,<xref ref-type="bibr" rid="bibr16-1352458511415890">16</xref></sup> and in different works published by other authors.<sup><xref ref-type="bibr" rid="bibr17-1352458511415890">17</xref></sup> These data show that oligoclonal IgM bands are useful as prognostic markers in adult onset MS.</p>
<p>Regarding the results of Stauch et al. in paediatric MS,<sup><xref ref-type="bibr" rid="bibr1-1352458511415890">1</xref></sup> we agree with this group in their first thesis, that is, their formula is not able to predict the course of children with suspected MS. Since they did not perform oligoclonal IgM analysis, it remains to be shown whether oligoclonal IgM bands are associated with an aggressive disease course in paediatric MS.</p>
<p>Nevertheless, we strongly disagree with their use of our previously published data to ascribe false positives to our results studied with other methods. If they want to compare the ability of different methods of studying intrathecal IgM synthesis to predict patient outcome they should analyse their samples with all of these methods. Since they have not reported a single oligoclonal IgM analysis, we think that they should not try to devalue other group work with no experimental basis.</p>
<p>Our main concern in this issue is that oligoclonal IgM band detection, when assayed with an adequate method, provides useful information to predict the outcome of MS patients in clinical practise. We hope future collaboration between groups working in the field will contribute to a standardization of the study of oligoclonal IgM bands and allow a more extended use of this technique in MS.</p>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Grant numbers: PS09/01652, PS09/01338 from the Fondo de Investigaciones Sanitarias and Red Española de Esclerosis múltiple (REEM) Spain.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511415890">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stauch</surname><given-names>C</given-names></name>
<name><surname>Reiber</surname><given-names>H</given-names></name>
<name><surname>Rauchenzauner</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: Quantitative versus qualitative IgM analysis</article-title>. <source>Mult Scler J</source> <year>2011</year>; <volume>17</volume>: <fpage>327</fpage>–<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511415890">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villar</surname><given-names>LM</given-names></name>
<name><surname>Masjuan</surname><given-names>J</given-names></name>
<name><surname>Gonzalez-Porque</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS</article-title>. <source>Neurology</source> <year>2002</year>; <volume>59</volume>: <fpage>555</fpage>–<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511415890">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersson</surname><given-names>M</given-names></name>
<name><surname>Alvarez-Cermeño</surname><given-names>JC</given-names></name>
<name><surname>Bernardi</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>1994</year>; <volume>57</volume>: <fpage>897</fpage>–<lpage>902</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511415890">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freedman</surname><given-names>MS</given-names></name>
<name><surname>Thompson</surname><given-names>EJ</given-names></name>
<name><surname>Deisenhammer</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement</article-title>. <source>Arch Neurol</source> <year>2005</year>; <volume>62</volume>: <fpage>865</fpage>–<lpage>870</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511415890">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pohl</surname><given-names>D</given-names></name>
<name><surname>Rostasy</surname><given-names>K</given-names></name>
<name><surname>Reiber</surname><given-names>H</given-names></name>
<name><surname>Hanefeld</surname><given-names>F</given-names></name>
</person-group>. <article-title>CSF characteristics in early-onset multiple sclerosis: A tool for early diagnosis</article-title>. <source>Neurology</source> <year>2004</year>; <volume>63</volume>: <fpage>1966</fpage>–<lpage>1967</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511415890">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reiber</surname><given-names>H</given-names></name>
<name><surname>Teut</surname><given-names>M</given-names></name>
<name><surname>Pohl</surname><given-names>D</given-names></name>
<name><surname>Rostasy</surname><given-names>KM</given-names></name>
<name><surname>Hanefeld</surname><given-names>F</given-names></name>
</person-group>. <article-title>Pediatric multiple sclerosis: Age related differences and time course of the neuroimmunological response in CSF</article-title>. <source>Mult Scler J</source> <year>2009</year>; <volume>15</volume>: <fpage>1466</fpage>–<lpage>1480</lpage>.</citation>
</ref>
<ref id="bibr7-1352458511415890">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaiser</surname><given-names>R</given-names></name>
<name><surname>Lücking</surname><given-names>CH</given-names></name>
</person-group>. <article-title>Intrathecal synthesis of IgM and IgA in neurological diseases: comparison of two formulae with isoelectric focusing</article-title>. <source>Clin Chim Acta</source> <year>1993</year>; <volume>216</volume>: <fpage>39</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511415890">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaiser</surname><given-names>R</given-names></name>
</person-group>. <article-title>Affinity immunoblotting: rapid and sensitive detection of oligoclonal IgG, IgA and IgM in unconcentrated CSF by agarose isoelectrofocusing</article-title>. <source>J Neurol Sci</source> <year>1991</year>; <volume>103</volume>: <fpage>216</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511415890">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sindic</surname><given-names>CJM</given-names></name>
<name><surname>Monteyne</surname><given-names>P</given-names></name>
<name><surname>Laterre</surname><given-names>EC</given-names></name>
</person-group>. <article-title>Occurrence of oligoclonal IgM bands in cerebrospinal fluid of neurological patients: an immunoaffinity-mediated capillary blot study</article-title>. <source>J Neurol Sci</source> <year>1994</year>; <volume>124</volume>: <fpage>215</fpage>–<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511415890">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smithies</surname><given-names>O</given-names></name>
</person-group>. <article-title>Disulfide-bond cleavage and formation in proteins</article-title>. <source>Science</source> <year>1965</year>; <volume>150</volume>: <fpage>1595</fpage>–<lpage>1598</lpage>.</citation>
</ref>
<ref id="bibr11-1352458511415890">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>R</given-names></name>
<name><surname>Euler</surname><given-names>B</given-names></name>
<name><surname>Rauer</surname><given-names>S</given-names></name>
</person-group>. <article-title>Intrathecal IgM synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event</article-title>. <source>Eur J Neurol</source> <year>2007</year>; <volume>14</volume>: <fpage>907</fpage>–<lpage>911</lpage>.</citation>
</ref>
<ref id="bibr12-1352458511415890">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villar</surname><given-names>LM</given-names></name>
<name><surname>González-Porqué</surname><given-names>P</given-names></name>
<name><surname>Masjuan</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Description of a sensitive and reproducible method for the detection of oligoclonal IgM bands</article-title>. <source>J Immunol Meth</source> <year>2001</year>; <volume>258</volume>: <fpage>151</fpage>–<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr13-1352458511415890">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villar</surname><given-names>LM</given-names></name>
<name><surname>Masjuan</surname><given-names>J</given-names></name>
<name><surname>Gonzalez-Porque</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Intrathecal IgM Synthesis in neurologic diseases: Relationship with disability in MS</article-title>. <source>Neurology</source> <year>2002</year>; <volume>58</volume>: <fpage>824</fpage>–<lpage>826</lpage>.</citation>
</ref>
<ref id="bibr14-1352458511415890">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villar</surname><given-names>LM</given-names></name>
<name><surname>Sádaba</surname><given-names>MC</given-names></name>
<name><surname>Roldán</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS</article-title>. <source>J Clin Invest</source> <year>2005</year>; <volume>115</volume>: <fpage>187</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr15-1352458511415890">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thangarajh</surname><given-names>M</given-names></name>
<name><surname>Gomez-Rial</surname><given-names>J</given-names></name>
<name><surname>Hedström</surname><given-names>AK</given-names></name>
<etal/>
</person-group>. <article-title>Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis</article-title>. <source>Mult Scler J</source> <year>2008</year>; <volume>14</volume>: <fpage>1208</fpage>–<lpage>1213</lpage>.</citation>
</ref>
<ref id="bibr16-1352458511415890">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boscá</surname><given-names>I</given-names></name>
<name><surname>Magraner</surname><given-names>MJ</given-names></name>
<name><surname>Coret</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands</article-title>. <source>J Neuroimmunol</source> <year>2010</year>; <volume>226</volume>: <fpage>143</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr17-1352458511415890">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mandrioli</surname><given-names>J</given-names></name>
<name><surname>Sola</surname><given-names>P</given-names></name>
<name><surname>Bedin</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease</article-title>. <source>J Neurol</source> <year>2008</year>; <volume>255</volume>: <fpage>1023</fpage>–<lpage>1031</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>